BEST PET RX IP, INC;Professional Compounding Centers of America (PCCA)
发明人:
Chris V. Simmons,Danny Carrero
申请号：
GB201612274
公开号：
GB2544843A
申请日:
2016.07.14
申请国别(地区):
GB
年份:
2017
代理人:
摘要：
A composition for treating cancer comprising an intralesional injection solution including at least one poloxamer(RTM) dissolved in a solvent and at least one anti-cancer active pharmaceutical ingredient dissolved in the injection solution. The anti-cancer active pharmaceutical ingredient may comprise a chemotherapeutic agent such as an alkylating agent or antimetabolite agent or an infectious disease virus programmed to infect the cancer. The concentration of the agent may be dependent upon the body surface area of the patient. The poloxamer(RTM) may be poloxamer 407 or poloxamer 188 or both. The poloxamer(RTM) concentration may be from 1% to 50%. The poloxamer(RTM) may be selected to inhibit the normal MDR proteins on the surface of cancer cells which make up the cancer. The poloxamer(RTM) may be a liquid upon injection and a gel following injection. The patient may be a companion animal such as a cat or dog.
